Aluda Publications

• Zhang, et al. SARs of a novel series of s-triazine compounds targeting vimentin to induce methuotic phenotype. Eur J Med Chem. 2021 Mar 15;214:113188. doi: 10.1016/j.ejmech.2021.113188.
• Wu, et al: A Small Vimentin-Binding Molecule Blocks Cancer Exosome Release and Reduces Cancer Cell Mobility. Frontiers in Pharmacol. 12:1597, 2021. doi: 10.3389/fphar.2021.627394.
• Li, et al. A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases. mBio. 2021 Oct 12:e0254221. doi: 10.1128/mBio.02542-21. Epub ahead of print. PMID: 34634931.
• Kim, et al. ALD-R491 regulates vimentin filament stability and solubility, cell contractile force, cell migration speed and directionality. Frontiers in Cell and Developmental Biology: 2022 Nov 22. doi: 10.3389/fcell.2022.926283.
• Wu J., et al: Therapeutic targeting of vimentin by ALD-R491 impacts multiple pathogenic processes to attenuate acute and chronic colitis in mice. Biomedicine & Pharmacotherapy. December, 2023. doi: 10.1016/j.biopha.2023.115648.
• Rosier, et al. The Vimentin-Targeting Drug ALD-R491 Partially Reverts the Epithelial-to-Mesenchymal Transition and Vimentin Interactome of Lung Cancer Cells. Cancers (Basel). 2024 Dec 30;17(1):81. doi: 10.3390/cancers17010081.
• Wu, et al. Oral Treatment with the Vimentin-Targeting Compound ALD-R491 Mitigates Hyperinflammation, Multi-Organ Injury, and Mortality in CLP-Induced Septic Mice. Life (Basel). 2025 Oct 6;15(10):1563. doi: 10.3390/life15101563.
• Chen, et al. Modulating Vimentin: A Systems-Level Therapeutic Strategy for Sepsis and Complex Diseases. Life (Basel). 2026 Mar 11; 16(3): 457. doi: 10.3390/life16030457.

This document was printed from http://www.aludapharm.com/science/publications.html